Key Market Indicators
American insulin imports are projected to decline to approximately $1.97 billion by 2028, down from around $2.07 billion in 2023. This represents a year-on-year compound annual growth rate (CAGR) decrease of 0.9%. Despite this anticipated drop, American demand for insulin has seen a yearly increase of 2.3% since 1996. In terms of exports, American insulin shipments are expected to fall to about $181 million by 2028, from roughly $195 million in 2023. This marks a 1.4% annual decrease in the compound growth rate. Notably, since 1996, the supply of American insulin for export has remained flat, showing no significant year-on-year increase.
